NCT01904799

Brief Summary

After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions. The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not suitable for aphasic patients because they contain items with a strictly verbal response. Because of this, inexperienced doctors cannot evaluate higher functions (other than language) of aphasics in routine practice. For the same reason, aphasics are regularly excluded from post-cva therapeutic protocols, whether or not the trial bears on the evolution of cognitive functions. Nonetheless, it is possible to evaluate, at least roughly, all of the cognitive functions without resorting to language. The investigator have developed , from validated tests and classical clinical manoeuvers, the Cognitive Assessment for Stroke Patients (CASP) :

  • for the rapid screening (less than 15 minutes) and quantification of post-cva cognitive disorders (6 functions: language, apraxia, short-term memory, temporal orientation, impaired spatial/visio-construction and executive functions);
  • the CASP can be used in most patients, including those with severe disorders of expression and moderate problems with comprehension, The format of these tests has been adapted so that severe disorders of expression (essentially left-hemisphere CVA), and left spatial impairment (right-hemisphere CVA) do not affect the ability to take the test. Its validity in terms of appearance and content were verified in 2011.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
263

participants targeted

Target at P75+ for not_applicable stroke

Timeline
Completed

Started Jan 2015

Longer than P75 for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 12, 2013

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 22, 2013

Completed
1.4 years until next milestone

Study Start

First participant enrolled

January 2, 2015

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 29, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 29, 2019

Completed
Last Updated

February 9, 2026

Status Verified

February 1, 2026

Enrollment Period

4.2 years

First QC Date

July 12, 2013

Last Update Submit

February 5, 2026

Conditions

Stroke

Outcome Measures

Primary Outcomes (6)

  • comprehensive assessment battery of higher functions

    baseline

  • comprehensive assessment battery of higher functions

    Evaluation at 3 ±1 days

  • comprehensive assessment battery of higher functions

    Evaluation at 6 ± 2 weeks

  • test of visual memory

    baseline

  • test of visual memory

    Evaluation at 3 ±1 days

  • test of visual memory

    Evaluation at 6 ± 2 weeks

Study Arms (1)

Cognitive Assessment

OTHER
Other: Cognitive Assessment test

Interventions

Cognitive Assessment testOTHER
Cognitive Assessment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For CVA patients
  • patients hospitalised in rehabilitation after a first recent hemispheric CVA (less than 6 weeks) ;
  • aged \> 18;
  • absence of severe disorders of oral comprehension (BDAE aphasia severity score \>2 for comprehension);
  • whatever the severity of oral expression disorders;
  • who have been given clear written and oral information, and after the doctor has verified their ability to understand the protocol.
  • For " Control " patients (to evaluate divergent validity)
  • patients hospitalised in rehabilitation units or geriatrics taking part in this study;
  • aged \> 18.

You may not qualify if:

  • For CVA patients
  • patients who do not speak French;
  • cognitive disorders known before the CVA;
  • psychotic disorders known before the CVA;
  • major visual disorders incompatible with reading, known before the CVA.
  • For " Control " patients (to evaluate divergent validity)
  • patients who do not speak French;
  • cognitive disorders known before the CVA;
  • psychotic disorders known before the CVA;
  • major visual disorders incompatible with reading, known before the CVA.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Dijon

Dijon, 21079, France

Location

Related Publications (1)

  • Benaim C, Wauquiez G, Perennou D, Piscicelli C, Lucas-Pineau B, Bonnin-Koang HY, Vuadens P, Binquet C, Bourredjem A, Devilliers H. Cognitive assessment scale for stroke patients (CASP): A multicentric validation study. Ann Phys Rehabil Med. 2022 May;65(3):101594. doi: 10.1016/j.rehab.2021.101594. Epub 2021 Nov 17.

    PMID: 34687958RESULT

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2013

First Posted

July 22, 2013

Study Start

January 2, 2015

Primary Completion

March 29, 2019

Study Completion

March 29, 2019

Last Updated

February 9, 2026

Record last verified: 2026-02

Locations

FR(1)